Patents Assigned to Cadila Healthcare Limited
  • Pharmaceutical compositions of anti-acne agents
    Patent number: 10028972
    Abstract: The present invention relates to pharmaceutical compositions for treatment of acne. In particular, the present invention relates to stable pharmaceutical compositions for treatment of acne along with other pharmaceutically acceptable excipients. These compositions exhibit excellent stability, greater permeability, and enhanced therapeutic efficacy. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: July 24, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jinesh Suresh Pancholi, Jitendra Dasharathlal Patel, Ravindra Mittal
  • Treatment for lipodystrophy
    Patent number: 10017470
    Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: July 10, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Dhiraj Gambhire, Rajendrakumar Hariprasad Jani, Bipin Pandey, Kaushik Sata, Himanshu Kothari, Pankaj Ramanbhai Patel
  • Heterocyclic compounds
    Patent number: 10011609
    Abstract: The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: July 3, 2018
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ranjit C. Desai, Brijeshkumar Srivastava
  • Crystalline form of rifaximin and process for its preparation
    Patent number: 9988398
    Abstract: A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 5, 2018
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh Singh, Nikhil Amar Singh, Prashant Rameshchandra Bhatt, Amol Kashinath Patil
  • SAROGLITAZAR MAGNESIUM FOR THE TREATMENT OF CHYLOMICRONEMIA SYNDROME
    Publication number: 20180125816
    Abstract: The present invention relates to the use of Saroglitazar Magnesium of formula (1), for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar Magnesium for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia.
    Type: Application
    Filed: May 10, 2016
    Publication date: May 10, 2018
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Mukul R. JAIN, Suresh GIRI
  • Synergistic compositions
    Patent number: 9957230
    Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: May 1, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
  • Polymorphic form of pyrrole derivative and intermediate thereof
    Patent number: 9951009
    Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 24, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Shri Prakash Dhar Dwivedi, Ramesh Chandra Singh, Vikas Patel, Amar Rajendra Desai
  • Amorphous form of linagliptin and process for preparation thereof
    Patent number: 9879011
    Abstract: The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 30, 2018
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Kuldeep Natwarlal Jain, Kumar Kamlesh Singh, Jitendra Maganbhai Gajera
  • Process for the preparation of dapagliflozin
    Patent number: 9845303
    Abstract: Dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: December 19, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Sanjay Jagdish Desai, Jayprakash Ajitsingh Parihar, Mahesh Laljibhai Rupapara
  • Polymorphic forms of ivabradine hydrochloride
    Patent number: 9840469
    Abstract: Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: December 12, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Mukul Hariprasad Sharma, Piyush Rajendra Sharma, Jayprakash Ajitsingh Parihar
  • Heterocyclic compounds
    Patent number: 9840509
    Abstract: The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 12, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Ranjit C. Desai, Rajesh Bahekar, Dipam Patel, Kiran Shah
  • NOVEL CRYSTALLINE FORM OF RIFAXIMIN AND PROCESS FOR ITS PREPARATION
    Publication number: 20170349608
    Abstract: A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.
    Type: Application
    Filed: June 6, 2017
    Publication date: December 7, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Prashant Rameshchandra BHATT, Amol Kashinath PATIL
  • Composition for nonalcoholic fatty liver disease (NAFLD)
    Patent number: 9814697
    Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: November 14, 2017
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Pankaj Patel, Rajendrakumar Hariprasad Jani
  • PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND INTERMEDIATES THEREOF
    Publication number: 20170320862
    Abstract: The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sanjay Jagdish DESAI, Jayprakash Ajitsingh PARIHAR, Alpesh Pravinchandra SHAH
  • SYNERGISTIC COMPOSITIONS OF IMMUNOSTIMULATING RECONSTITUTED INFLUENZA VIROSOMES WITH IMMUNOPOTENTIATORS AND VACCINES CONTAINING THEM
    Publication number: 20170296638
    Abstract: The present invention is directed to a preparation of an adjuvant system to achieve required level of humoral and cellular immune response against antigen of interest. The current invention provides an adjuvant system comprising an immunostimulating reconstituted influenza virosomes (IRIVs) and immunopotentiators. The current invention illustrates that an antigen is adsorbed or incorporated into IRIVs and further formulated with lipophilic adjuvant such as MPL or glucopyranosyl lipid adjuvant (synthetic analogue of MPL).
    Type: Application
    Filed: September 1, 2015
    Publication date: October 19, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Gaurav GUPTA, Epifanio FICHERA, Reinhard GLUECK
  • Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
    Patent number: 9789123
    Abstract: Stable pharmaceutical compositions and processes for making same for the treatment of psoriasis. The compositions may be nanoemulsions having nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. The compositions exhibit improved permeability and bioavailability.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Treatment for lipodystrophy
    Patent number: 9783495
    Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 10, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Bipin Pandey, Kaushik Sata, Himanshu Kothari, Pankaj R. Patel
  • AMORPHOUS FORM OF DACLATASVIR AND ITS SALTS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20170281599
    Abstract: This relates to an amorphous form of daclatasvir and its salts and process for preparation thereof. In particular, it relates to an amorphous form of daclatasvir and daclatasvir dihydrochloride. It also relates to pharmaceutical compositions comprising an amorphous form of daclatasvir or daclatasvir dihydrochloride for oral administration for treatment of Hepatitis C virus (HCV).
    Type: Application
    Filed: March 28, 2017
    Publication date: October 5, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sanjay Jagdish DESAI, Sandipan Prabhurao BONDGE, Naitik Bharatbhai PATEL, Chirag Vasantbhai PATEL, Sandip Kiritkumar UPADHYAY
  • Processes for the preparation of lorcaserin
    Patent number: 9714225
    Abstract: The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: July 25, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Jayprakash Ajitsingh Parihar, Alpeshkumar Pravinchandra Shah, Samir Rameshbhai Gajjar, Brij Khera
  • Method for treatment of pain and inflammation
    Patent number: 9713590
    Abstract: The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: July 25, 2017
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ravindra Mittal, Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh